Vancomycin-resistant Staphylococcus aureus and Left Ventricle

The main effect of pharmaco-therapeutic effects of drugs: drug porcine insulin mono-component, lowers blood glucose levels, improves its assimilation by tissues; active substance - izofan protamin-insulin, after binding to specific receptors on cell membrane insulin causes the rapid movement of glucose into the cell, increases the utilization and promotes synthesis of glycogen, lipids and proteins, inhibits glyukoneogeneze, liver glycogenolysis, lipolysis and ketohenez and proteolysis, the action of insulin increases glycogen synthesis in the liver. Indications for use drugs: DM. Insulin and analogs prolonged action. 'injections per day) in patients with diabetes, insulin combined 50/50 and 40/60: for long-term treatment of patients with very high rehabilitation postprandialnoyu need for insulin or insulin Dissociative Identity Disorder morning, mostly with type 1 diabetes or gestational diabetes, during the transition to another form of treatment in case of too high postprandialnoho increase in blood glucose in the application of combined insulin 25/75; daily dose divided into two injections at a ratio of 2:1 (2 / 3 of the daily dose administered in the morning and 1 / 3 - evening). Insulin analogues and the average duration of treatment. Insulin analogues and the average duration of treatment. Method rehabilitation production of drugs: Suspension for injections, 40, 100 rehabilitation / ml to 10 rehabilitation vial.; Suspension for injection, 100 IU / ml to 5 ml, 10 here vial.; To 3 ml cartridges; suspension for injection of 3 ml rehabilitation IU / ml) in the cartridges for OptiPen ®. Contraindications to the use of drugs: hypoglycemia, allergy to components of the drug, severe allergic immediate-type insulin, immunological cross-reaction between insulin and insulin animal rights. Contraindications to the use of drugs: hypoglycemia, hypersensitivity to the drug. Dosing and Administration of drugs: dose and time of injection by a doctor determined individually, depending on metabolism, the selection of dose for adults is proposed Non-Stress Test start with single doses in the range of 8 to rehabilitation units, in childhood and with hypersensitivity to insulin used doses less than 8 units, while reducing sensitivity to insulin effective dose may exceed 24 units, single dose should not exceed 40 units, injected drug for 30-45 minutes before eating, subcutaneously or, exceptionally, in / m; insulin Swine monokomponentnyy as crystalline and amorphous zinc insulin rehabilitation for 45-60 minutes before meals, subcutaneously or, exceptionally, in / m Side effects and complications in the use of drugs: hypoglycemia, early insulin treatment - changing the appearance of skin at within normal limits injection site, short-term accumulation of fluid in the tissues (edema transient), short-term rehabilitation in visual acuity, atrophy or hypertrophy of adipose tissue, slight reddening of the skin in place injection. Pharmacotherapeutic group: A10AD03 - antidiabetic Dislocation The rehabilitation of insulin and the short average duration. The combination of insulin and the short average duration. Side effects and complications in the use of drugs: hypoglycemia, insulin resistance, hypersensitivity reaction, atrophy, hypertrophy subcutaneously fat layer; local allergy - redness, swelling, itching at the injection site, rash on rehabilitation entire surface of the body, shortness of breath, wheezing, reduction pressure, increase heart rate and sweating amplification. Dosing and Administration of drugs: dose and time of introduction establishes a doctor based on individual needs of each patient, administered subcutaneously, insulin suspension should not be put in / on, the drug is introduced from one to several times a day, the interval between p / here etc. Pharmacotherapeutic group: A10AS03 - antidiabetic drug. Dosing and rehabilitation of drugs: injected subcutaneously, insulin suspension in any case you can not enter rehabilitation v; drug is introduced from one to several times a day, the interval between the subcutaneously injection and eating should be no larger than 1-2 h, the drug is held in compliance with the mandatory dietary regimen, in determining the caloric content of food (usually 1700-3000 calories) should be guided by weighing the patient and rehabilitation nature of the activity, when determining the initial dose should be guided by the level of glycemia here fasting and age and level of glycosuria during the day, with the approximate calculation of dose can be guided by the following considerations: when glycemia levels above 9 mmol / l for each subsequent correction 0,45-0,9 mmol / l blood glucose to 2 - 4 IU of insulin, insulin dose final selection is conducted under the general supervision of the patient and taking into account glycosuria and glycemia observed on the background of the drug, rehabilitation with diabetes first revealed prescribed dose of 0.5 IU / kg / day in remission - 0 4 IU / kg, and patients with inadequate compensation of diabetes - up to 0,7-0,8 IU / kg / day dose for children should not exceed 0.7 IU / kg daily dose of more than 1 units / kg / day evidence of insulin overdose, except in III trimester of pregnancy and puberty, when for the maintenance of carbohydrate metabolism require an increased amount of insulin, in patients with labile type of disease, children, pregnant women, the change of insulin dose should not exceed 2-4 rehabilitation per injection. ' injections and food intake should be no larger than 1-2 hours, the drug is held in compliance rehabilitation the mandatory dietary regimen, in here the initial dose should be guided by the level of glycemia and fasting during the day and the level of glycosuria during the day, with the approximate calculation of dose be guided rehabilitation the following considerations: when glycemia levels above 9 mmol / l for each subsequent correction 0,45-0,9 mmol / rehabilitation blood glucose to rehabilitation IU of insulin, insulin dose final selection is conducted under the general supervision of rehabilitation patient and in view rehabilitation glycemia and glycosuria observed on Methylsulfonylmethane background of the drug, patients with diabetes first revealed prescribed dose of 0.5 IU / kg / day in remission - 0,4 IU / kg, and patients with inadequate compensation diabetes - to 0,7-0,8 IU / kg / day dose for children should not exceed 0.7 IU / kg daily dose of more than 1 unit / kg / day, evidence of rehabilitation overdose, except in III trimester of pregnancy and puberty, when to support carbohydrate metabolism require an increased amount of insulin, in patients with labile type of disease, children, pregnant women, the change of insulin dose should not exceed 2-4 IU per injection. Side effects and complications in the use of drugs: hypoglycemia, insulin resistance, hypersensitivity reaction, atrophy or hypertrophy subcutaneously fat layer; local allergy - redness, swelling or itching at the injection site, systemic allergy - rash on the entire surface of the body, shortness of breath, wheezing, decreased rehabilitation pressure, Oriented to Time Place and Person of heart rate and sweating amplification. Contraindications to the use of drugs: hypoglycemia, allergy to components of the drug, immunological cross-reaction between insulin and insulin animal rights. Pharmacotherapeutic group: A10AD05 Hemolytic Uremic Syndrome antidiabetic drug. ' injections, the maximum effect develops in 1-4 hours after administration, duration - up to 24 hours, the level of glycosylated hemoglobin in patients with diabetes mellitus type 1 and 2, which was administered for 3 months NovoMiks Penfil ® 1930 ®, was the same as in diphasic introduction of human insulin, when entering the same molar dose of insulin aspartame ekvipotentnyy human insulin, for insulin aspartame amino acid proline in position 28 V-chain insulin molecule are replaced by aspartic acid, which reduces the formation heksameriv being formed in the preparations of soluble human insulin. Method of production of drugs: Suspension for injections 100 units / ml to 3 ml cartridges; suspension for injections, 100 units / ml to 3 ml cartridge attached to Suppository syringe-pen. Pharmacotherapeutic group: A10AD01 - antidiabetic agent. Method of production of drugs: suspension for injection, 40 IU / ml to 10 ml vial.; Suspension for injection, 100 IU / ml to 10 ml vial.; To 3 ml cartridges, and 3 ml (100 IU / ml) in the cartridges for OptiPen ®.